Best of ASCO - 2014 Annual Meeting



Attend this session at the
2018 ASCO Annual Meeting!

Session: Genitourinary (Prostate) Cancer

Type: Poster Session

Time: Saturday June 2, 1:15 PM to 4:45 PM

Location: Hall A

The association of BRCA1 and BRCA2 mutations on prostate cancer risk, frequency, and mortality: Systematic review and meta-analysis.


Genitourinary (Prostate) Cancer

2018 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Session (Board #287)

J Clin Oncol 36, 2018 (suppl; abstr 5060)

Author(s): Mok Oh, Rana Aljadeed, Nasser Mubarak Al Khushaym, Abdulhamid Althagafi, Saad Fallatah, Hani M. Babiker, Ali McBride, Ivo Abraham; University of Arizona College of Pharmacy, Tucson, AZ; University of Arizona Cancer Center, Tucson, AZ

Abstract Disclosures


Background: A prior meta-analysis (Fachal, Prostate, 2011) suggested no association between BRCA1 mutation and prostate cancer (PCa). Several additional BRCA2 studies have shown an association with PCa risk and mortality. We conducted a systematic review and meta-analysis of BRCA1 and BRCA2 studies to estimate PCa risk in BRCA mutation carriers, evaluate the frequency of BRCA mutation carriers in PCa patients (pts) and compare survival rate among BRCA mutation carriers and non-carriers. Methods: PubMed/MEDLINE, Embase and Cochrane databases were searched for relevant studies for the above objectives. Meta-analyses were conducted using unadjusted odds ratio (OR) with 95% confidence interval (95%CI) for PCa incidence; frequency (%) of BRCA mutation in PCa pts; and hazard ratio (HR) with 95%CI for cancer-specific survival (CSS) and overall survival (OS). Random effects analyses were performed for overall BRCA (BRCA1 or BRCA2), with subgroup analyses for BRCA1 and BRCA2 separately. Results: 10 cohort, 10 case-control, 38 frequency and 11 survival studies were included. Being a BRCA carrier was associated with a significant increase in PCa risk (OR 1.97, 95%CI 1.60-2.42), with BRCA2 mutation being associated with a greater risk of PCa (OR 2.72, 95%CI 2.10-3.54) than BRCA1 (OR 1.39, 95%CI 1.07-1.81). The frequency of BRCA1 and BRCA2 carriers in PCa patients was 1.8% and 2.7% respectively. OS (HR 2.21, 95%CI 1.64-2.30) and CSS (HR 2.63, 95%CI 2.00-3.45) were significantly worse among BRCA2 carriers compared to non-carriers, whereas OS (HR 0.47, 95%CI 0.11-1.99) and CSS (HR 1.07, 95%CI 0.38-2.96) were not statistically significant when comparing BRCA1 carriers and non-carriers. Conclusions: Meta-analyses revealed a 1.97-fold greater risk of prostate cancer in overall BRCA mutation carriers. This elevated PCa risk was attributable largely to a 2.72-fold greater risk of PCa in BRCA2 carriers and a moderate 1.39-fold greater risk in BRCA1 carrier. BRCA2, but not BRCA1, mutations were associated with higher PCa mortality. BRCA mutation may be a clinical factor to stratify high-risk patients and provide clinical strategies for more effective targeted treatments for patients with PCa.

Other Abstracts in this Sub-Category:


1. The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).

Meeting: 2018 ASCO Annual Meeting Abstract No: 5004 First Author: Andrew J. Armstrong
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes


2. Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).

Meeting: 2018 ASCO Annual Meeting Abstract No: 5058 First Author: Antoine Thiery Vuillemin
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes


3. Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).

Meeting: 2018 ASCO Annual Meeting Abstract No: 5059 First Author: Tian Zhang
Category: Genitourinary (Prostate) Cancer - Biomarkers/Epidemiology/Outcomes